EDMA
 | |
| Clinical data | |
|---|---|
| Other names | EDMA |
| Routes of administration | Oral |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C12H17NO2 |
| Molar mass | 207.273 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| (verify) | |
3,4-Ethylenedioxy-N-methylamphetamine (EDMA) is an entactogen drug of the methamphetamine class.[1][2] It is an analogue of MDMA where the methylenedioxy ring has been replaced by an ethylenedioxy ring.[1][2] EDMA was first synthesized by Alexander Shulgin.[1] In his book PiHKAL, the dosage is listed as 150–250 mg, and the duration listed as 3–5 hours.[1] According to Shulgin, EDMA produces a bare threshold consisting of paresthesia, nystagmus, and hypnogogic imagery, with few to no other effects.[1]
It has been found that EDMA acts as a non-neurotoxic serotonin releasing agent with moderately diminished potency relative to MDMA, and with negligible effects on dopamine release.[2] However, subsequent research found that EMDA is a serotonin–norepinephrine–dopamine releasing agent (SNDRA) with EC50 values of 117 nM for serotonin release, 325 nM for norepinephrine release, and 597 nM for dopamine release in rat brain synaptosomes.[3] Compared to MDMA, EDMA was about half as potent as a serotonin releaser, 4.5-fold less potent as a norepinephrine releaser, and 8-fold less potent as a dopamine releaser.[3] The activities of the individual enantiomers of EDMA have also been assessed.[3]
See also
- 3,4-Ethylenedioxyamphetamine (EDA)
- 3,4-Ethylenedioxymethcathinone (EDMC)
- 3,4-Ethylidenedioxyamphetamine (EIDA)
- 3,4-Isopropylidenedioxyamphetamine (IDA)
References
- ^ a b c d e Shulgin A, Shulgin A (1991). Pihkal: A Chemical Love Story. Transform Press. ISBN 0-9630096-0-5.
- ^ a b c McKenna DJ, Guan XM, Shulgin AT (March 1991). "3,4-Methylenedioxyamphetamine (MDA) analogues exhibit differential effects on synaptosomal release of 3H-dopamine and 3H-5-hydroxytryptamine". Pharmacology, Biochemistry, and Behavior. 38 (3): 505–512. doi:10.1016/0091-3057(91)90005-M. PMID 1829838. S2CID 2740262.
- ^ a b c Del Bello F, Sakloth F, Partilla JS, Baumann MH, Glennon RA (September 2015). "Ethylenedioxy homologs of N-methyl-(3,4-methylenedioxyphenyl)-2-aminopropane (MDMA) and its corresponding cathinone analog methylenedioxymethcathinone: Interactions with transporters for serotonin, dopamine, and norepinephrine". Bioorg Med Chem. 23 (17): 5574–5579. doi:10.1016/j.bmc.2015.07.035. PMC 4562428. PMID 26233799.